MECHL, Zdeněk, Jana NEUWIRTHOVÁ, Petr BURKOŇ, Pavel SMILEK and Rom KOSTŘICA. Aktuální klinické informace - Erbitux (cetuximab) - Nádory hlavy a krku (Actual clinical information - Erbitux (cetuximab) - Head and neck cancers). 1st ed. Praha: Merck oncology, 2008, 18 pp.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Aktuální klinické informace - Erbitux (cetuximab) - Nádory hlavy a krku
Name in Czech Aktuální klinické informace - Erbitux (cetuximab) - Nádory hlavy a krku
Name (in English) Actual clinical information - Erbitux (cetuximab) - Head and neck cancers
Authors MECHL, Zdeněk, Jana NEUWIRTHOVÁ, Petr BURKOŇ, Pavel SMILEK and Rom KOSTŘICA.
Edition 1. vyd. Praha, 18 pp. 2008.
Publisher Merck oncology
Other information
Original language Czech
Type of outcome Popularizing texts and activities
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
Keywords (in Czech) karcinomy hlavy a krku - cílená léčba - cetuximab - inhibice EGFR - prediktivní markery
Keywords in English head and neck cancer targeted therapy cetuximab EGFR inhibition predictive markers
Tags cetuximab, EGFR inhibition, head and neck cancer, predictive markers, targeted therapy
Changed by Changed by: doc. MUDr. Pavel Smilek, Ph.D., učo 1801. Changed: 10/2/2010 09:04.
Abstract
Autoři popisují současné možnosti léčby karcinomů hlavy a krku a zaměřují se hlavně na cílenou léčbou
Abstract (in English)
auithors describe possibility of the treatment of head and neck cancers and they are focusing on targeted therapy
PrintDisplayed: 28/7/2024 06:25